KALA BIO, Inc. Common Stock (KALA)

Price$2.20

Value ScoreD

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-109.06%

Price vs S&P 500 (4W)-64.05%

VGM Score19.85

Market Capitalization$41.46M

All Metrics

Book Value / Share (Quarterly)$44.23

P/TBV (Annual)0.88x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-216.04

Price vs S&P 500 (YTD)-102.91%

Gross Margin (TTM)30.96%

Net Profit Margin (TTM)-1383.48%

EPS (TTM)$-136.77

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-136.77

EPS (Annual)$-10.26

ROI (Annual)-91.19%

Gross Margin (Annual)34.19%

Net Profit Margin (5Y Avg)-7795.15%

Cash / Share (Quarterly)$141.91

ROA (Last FY)-70.29%

EBITD / Share (TTM)$-7.82

ROE (5Y Avg)-413.54%

Operating Margin (TTM)-1261.57%

Cash Flow / Share (Annual)$-242.90

P/B Ratio7.26x

P/B Ratio (Quarterly)6.48x

Net Income / Employee (Annual)$-6,500,000

EV / Revenue (TTM)8.48x

Net Interest Coverage (TTM)-12.60x

ROA (TTM)-86.99%

EPS Incl Extra (Annual)$-10.26

Current Ratio (Annual)3.11x

Quick Ratio (Quarterly)0.65x

3-Month Avg Trading Volume0.12M

52-Week Price Return-98.84%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.17

P/S Ratio (Annual)10.66x

Asset Turnover (Annual)0.04x

52-Week High$1030.00

Operating Margin (5Y Avg)-7404.03%

EPS Excl Extra (Annual)$-10.26

CapEx CAGR (5Y)-62.19%

Tangible BV CAGR (5Y)-26.70%

26-Week Price Return-93.13%

Quick Ratio (Annual)3.02x

13-Week Price Return-88.26%

Total Debt / Equity (Annual)2.47x

Current Ratio (Quarterly)0.75x

Enterprise Value$48.77M

Asset Turnover (TTM)0.05x

Book Value / Share Growth (5Y)19.00%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.60x

Pretax Margin (Annual)-1152.19%

Cash / Share (Annual)$420.14

3-Month Return Std Dev130.06%

Net Income / Employee (TTM)$-3,275,700

ROE (Last FY)-316.25%

Net Interest Coverage (Annual)-11.63x

EPS Basic Excl Extra (Annual)$-10.26

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)5.37x

EPS Incl Extra (TTM)$-136.77

Receivables Turnover (Annual)0.00x

ROI (TTM)-83.84%

P/S Ratio (TTM)7.21x

Pretax Margin (5Y Avg)-7795.15%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$11.12

Price vs S&P 500 (52W)-127.04%

Year-to-Date Return-91.98%

5-Day Price Return-8.23%

EPS Normalized (Annual)$-10.26

ROA (5Y Avg)-69.35%

Net Profit Margin (Annual)-1152.19%

Month-to-Date Return-57.52%

Cash Flow / Share (TTM)$-21.40

EBITD / Share (Annual)$-10.72

Operating Margin (Annual)-958.61%

LT Debt / Equity (Annual)1.63x

ROI (5Y Avg)-94.88%

LT Debt / Equity (Quarterly)2.65x

EPS Basic Excl Extra (TTM)$-136.77

P/TBV (Quarterly)1.49x

P/B Ratio (Annual)3.43x

Inventory Turnover (TTM)0.60x

Pretax Margin (TTM)-1383.48%

Book Value / Share (Annual)$101.23

Price vs S&P 500 (13W)-98.01%

Beta-2.57x

Revenue / Share (TTM)$0.00

ROE (TTM)-366.61%

52-Week Low$2.10

vGradeD

mGradeF

vgmGradeF

Show chart for

Earnings Surprise History

Q4 25-33.50est. -73.44

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

2.29

2.17

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
KALAKALA BIO, Inc. Common Stock	D	—	F	$2.20
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Kala Bio is a clinical-stage biopharmaceutical company developing cell-derived therapies for rare eye diseases. The company's lead candidate, KPI-012, is a human mesenchymal stem cell product designed to restore corneal healing and treat severe retinal degenerative diseases including Retinitis Pigmentosa and Stargardt Disease. KPI-012 leverages multiple therapeutic factors including growth factors and neuroprotective proteins to address unmet needs in vision-threatening conditions.